Home » Newsletters » BioWorld Science

BioWorld Science

April 30, 2019

View Archived Issues

Pembrolizumab treatment in patients with progressive multifocal leukoencephalopathy

Proteomics enriches genomics for colon cancer understanding

Lilly presents LY-3410738, a new IDH1 inhibitor with potential for treating cancer

Characterization of OG-716, a novel lantibiotic for the treatment of Clostridium difficile infection

GIRK activator VU-0466551 shows analgesic effects alone or combined with morphine in pain models

From bile to biofilm, and back

Dietary supplement increases brown fat activity

Vafidemstat improves aggression, other ADHD symptoms in REIMAGINE trial

Potential Hep B immunotherapeutic target identified

Momenta Pharmaceuticals presents best-in-class anti-CD38 therapeutic

LncRNA LINC01614 as a novel biomarker of poor survival in HNSCC

Biocad CJSC identifies EGFR Leu858Arg/Thr790Met double mutant inhibitors

Sidecar Therapeutics describes new MAP3K5 inhibitors

Patient enrollment begins in phase I study of CS1-CAR T therapy for multiple myeloma

Ubiquitin carboxyl-terminal hydrolase 30 inhibitors discovered at FORMA Therapeutics

Bristol-Myers Squibb synthesizes new galectin 3 inhibitors

Janssen initiates first-in-human study of JNJ-67856633

Zhejiang University patents agents targeting ephrin-A1

IL-32 identified as a marker for NAFLD diagnosis

I-Mab begins dosing in phase III study of TJ-202 for multiple myeloma

FDA approves etanercept biosimilar Eticovo

FDA approves IND application for TNB-383B

Orasis Pharmaceuticals' CSF-1 provides improvement in presbyopia

U.K. MHRA approves CTA for first-in-human study of DYN-101 for centronuclear myopathies

New report recommends immediate and coordinated action to avert drug-resistance crisis

Aptinyx reports phase I data for NMDA receptor modulator NYX-458

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...